The Role of KMT2Ar/NPM1 and Menin in Relapsed/Refractory AML

EP: 1.Acute Myeloid Leukemia: Patient Presentation and Evaluating Response

EP: 2.Acute Myeloid Leukemia Subtypes and Risk Stratification

Now Viewing

EP: 3.The Role of KMT2Ar/NPM1 and Menin in Relapsed/Refractory AML

EP: 4.Recent Data in Relapsed/Refractory Acute Myeloid Leukemia

EP: 5.Ongoing Research and Future Perspectives in Relapsed/Refractory AML

EP: 6.Clinical Pearls for Community Oncologists Treating Relapsed/Refractory AML

EP: 7.Menin Inhibitors Show Promise in Future AML Treatment

This is a video synopsis/summary of an OncView® featuring Ghayas C. Issa, MD.

Issa explains that KMT2A rearrangements involve 2 chromosomes abnormally fused and resembling crossed wires, leading to abnormal signaling and leukemia development. For this abnormal gene expression to occur, it requires the cofactor menin. By disrupting menin-KMT2A interaction, the abnormal leukemia-causing gene expression is shut down.

He elaborates on prognostic nuances of the 2 main genotypes targeted by menin inhibition. Newly diagnosed NPM1 mutant acute myeloid leukemia (AML) usually has a good prognosis with standard therapy and high remission/cure rates, though a small subset relapses. By contrast, newly diagnosed KMT2A leukemias most often have adverse prognosis regardless of the specific translocation. While 9;11 translocations fare slightly better than other KMT2A variants, the difference is minimal, especially in older patients or those not getting intensive chemotherapy.

In the relapsed/refractory setting, outcomes tend to be poor regardless of genetics. However, they are particularly dismal with KMT2A rearrangements. For relapsed NPM1 mutant AML, presence of the mutation does not affect prognosis; once relapsed, it confers similarly poor outcomes as other relapsed acute leukemias.

Video synopsis is AI-generated and reviewed by Cancer Network® editorial staff.